论文部分内容阅读
目的:比较不同剂量雷贝拉唑为基础的含铋四联10 d疗法幽门螺杆菌Helicobacter pylori根除率和症状缓解率。方法:H.pylori阳性的胃炎或十二指肠溃疡患者随机接受包含不同剂量雷贝拉唑的四联疗法:雷贝拉唑10 mg(A组)或20 mg(B组)、克拉霉素500 mg、阿莫西林1 000 mg和枸橼酸铋钾220 mg,bid,疗程10 d。停药4周后复查13C-呼气试验,并了解症状缓解情况。结果:共有121例患者纳入本试验,其中A组60例,B组61例。A组H.pylori根除率为83.3%(意向分析,ITT,符合方案分析,PP),B组H.pylori根除率为91.8%(ITT),94.9%(PP);A组疼痛缓解率为81.3%(ITT,PP),B组疼痛缓解率为93.5%(ITT),95.6%(PP)。按PP群组分析B组H.pylori根除率及疼痛缓解率明显高于A组,按ITT组群分析,两组方案H.pylori根除率及疼痛缓解率无明显差异。结论:含大剂量雷贝拉唑的含铋四联10 d疗法较标准剂量雷贝拉唑四联疗法可以获得更高的H.pylori根除率及疼痛缓解率。
OBJECTIVE: To compare the eradication rates and symptom relief rates of Helicobacter pylori in rabbits treated with different doses of rabeprazole for 10 days. METHODS: Patients with H.pylori-positive gastritis or duodenal ulcer were randomized to receive quadruple therapy with different doses of rabeprazole: rabeprazole 10 mg (group A) or 20 mg (group B), clarithromycin 500 mg, amoxicillin 1000 mg and bismuth potassium citrate 220 mg bid for 10 days. Review the 13C-breath test after 4 weeks of withdrawal and learn about the symptom relief. Results: A total of 121 patients were enrolled in this study, including 60 patients in group A and 61 patients in group B. In group A, H.pylori eradication rate was 83.3% (intention analysis, ITT, in line with protocol analysis, PP). The H.pylori eradication rate in group B was 91.8% (ITT) and 94.9% (PP) respectively. The pain relief rate in group A was 81.3 % (ITT, PP). The pain relief rate in group B was 93.5% (ITT) and 95.6% (PP). By PP group analysis of B group H.pylori eradication rate and pain relief rate was significantly higher than the A group, according to the ITT group analysis, two programs H.pylori eradication rate and pain relief rate was no significant difference. CONCLUSION: Compared with the standard dose of rabeprazole quadruple therapy, the bismuth-containing quadruple 10-day therapy with high-dose rabeprazole can achieve higher H.pylori eradication rate and pain relief rate.